Compass Therapeutics, Inc.
NASDAQ:CMPXBiotechnology
-$0.03 today
- Market cap
- $109.26M
- Beta
- 0.74
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.37
Volume 2.90M
Average 7.64M
Big Five Numbers
Compass Therapeutics, Inc. growth analysis
Start with the long-run numbers that show whether CMPX compounds: return on capital and growth in sales, earnings, equity, and free cash flow.
Big Five Numbers
CAGR by period · ROIC shows average
| Metric | 10yr | 5yr | 3yr | 1yr |
|---|---|---|---|---|
EPS | N/A | N/A | N/A | N/A |
Revenue | N/A | N/A | N/A | N/A |
Equity | N/A | N/A | -10.3% | +36.6% |
Cash | N/A | N/A | -4.3% | -29.5% |
ROIC | N/A | -38.2% | -37.2% | -35.3% |
Analysis
Latest growth is strongest in Equity at +36.6% and weakest in ROIC at -35.3%. Three-year average ROIC is -37.2%, which helps show whether that growth is being earned efficiently.
Growth analysis
Is growth accelerating or fading?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A11 analysts |
| Revenue | N/A | N/A | N/A | N/A12 analysts |
| Net Income | N/A | N/A | N/A | N/A12 analysts |
| EBIT | N/A | N/A | N/A | N/A12 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Revenue segments
Where does the growth come from?
Break revenue down by product and geography to see which parts of the business drive the trend.
Revenue by segment
Where CMPX earns its revenue, as reported in company filings
This company does not report revenue segments.
Free cash flow
Does growth turn into cash?
Check whether reported growth converts into free cash flow after capital spending.
Free Cash Flow
Net Income to FCF bridge
FY2025
Analysis
FY2025 free cash flow is -$49.2M. FCF conversion is 73.9% of net income. Operating cash flow was -$49.1M, with capex of -$25.0K. The largest bridge item is Working Capital at $9.2M.
Price targets
What do analysts expect from the price?
Compare the current price with the low, average, and high analyst targets.
Wall Street price targets
1-year price history with analyst consensus target
Unlock analyst target range
Sign in free to see low, average, high targets and implied upside for CMPX.
Analyst ratings
How do analysts rate the stock?
Review the buy, hold, and sell split and recent upgrades and downgrades.
Analyst ratings
Buy, hold, and sell recommendations and recent rating changes
Unlock analyst ratings
Sign in free to see the buy/hold/sell breakdown and recent rating changes for CMPX.
Competitor growth
How does Compass Therapeutics, Inc. grow against peers?
Compare historical and forecast growth with similar companies.
Competitor Growth
Peer CAGR comparison & forward estimates
| Company | Market Cap | 10yr | 5yr | 3yr | Fwd |
|---|---|---|---|---|---|
KalVista Pharmaceuticals, Inc. KALV | $1.44B | +42.5% | — | — | +68.2% (4yr)3 analysts |
Omeros Corporation OMER | $1.27B | — | — | — | —1 analysts |
Corvus Pharmaceuticals, Inc. CRVS | $897.52M | — | — | — | —3 analysts |
Lexicon Pharmaceuticals, Inc. LXRX | $796.97M | -9.1% | +15.7% | +610.3% | +39.1% (5yr)3 analysts |
4D Molecular Therapeutics, Inc. FDMT | $675.64M | — | +44.3% | +200.9% | +37.5% (5yr)3 analysts |
Monopar Therapeutics Inc. MNPR | $483.28M | — | — | — | —6 analysts |
Fulcrum Therapeutics, Inc. FULC | $287.64M | — | — | — | —2 analysts |
Ocugen, Inc. OCGN | $280.88M | — | +152.5% | +21.0% | +203.3% (5yr)2 analysts |
Bicycle Therapeutics plc BCYC | $236.22M | — | +47.5% | +71.2% | +12.4% (5yr)4 analysts |
Gossamer Bio, Inc. GOSS | $67.10M | — | — | — | +41.3% (5yr)5 analysts |
Questions
Growth questions
Common questions about CMPX's growth, answered from reported and forecast figures.
Is CMPX growing revenue?
Revenue declined 100.0% year over year, from $850,000.00 to $0.00.
Continue the stock analysis
Jump to another research area for this company.